Natixis’s Cymabay Therapeutics CBAY Stock Holding History

Natixis’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-32,951	Closed	-$150K	–	1164
2021 Q1	$150K	Sell	32,951 -2,073	-6%	-$11.2K	﹤0.01%	1034
2020 Q4	$201K	Buy	+35,024	New	+$265K	﹤0.01%	1006

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Natixis's CBAY Position: Q2 2021 in Review

Natixis sold out of Cymabay Therapeutics (CBAY) in Q2 2021, closing a stake of 32,951 shares — an estimated $150K sold.

Natixis first reported a position in CBAY in Q4 2020 and held it in 2 quarters. The position peaked at $201K in Q4 2020. 113 funds tracked by Wall St. Rank hold CBAY as of Q2 2021.

Natixis reported no remaining Cymabay Therapeutics position as of Q2 2021 after selling out during the quarter.
Natixis sold 32,951 Cymabay Therapeutics shares in Q2 2021, an estimated $150K.
Natixis first reported a position in Cymabay Therapeutics in Q4 2020 and held it in 2 quarters.
Natixis's Cymabay Therapeutics position peaked at $201K in Q4 2020.
113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2021.

Based on Natixis's 13F filing for Q2 2021, filed 13 Aug 2021.